4512 Stock Overview
Wakamoto Pharmaceutical Co.,Ltd. manufactures and sells ethical and non-prescription drugs in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wakamoto Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥232.00 |
| 52 Week High | JP¥261.00 |
| 52 Week Low | JP¥189.00 |
| Beta | 0 |
| 1 Month Change | 10.48% |
| 3 Month Change | 9.95% |
| 1 Year Change | -6.07% |
| 3 Year Change | -37.63% |
| 5 Year Change | -16.25% |
| Change since IPO | -66.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4512 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.9% | -1.0% | 1.8% |
| 1Y | -6.1% | 5.9% | 33.5% |
Return vs Industry: 4512 underperformed the JP Pharmaceuticals industry which returned 5.9% over the past year.
Return vs Market: 4512 underperformed the JP Market which returned 33.5% over the past year.
Price Volatility
| 4512 volatility | |
|---|---|
| 4512 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.3% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4512 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4512's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | n/a | Arata Igarashi | www.wakamoto-pharm.co.jp |
Wakamoto Pharmaceutical Co.,Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation; and Wakamoto Intestinal Remedy drug.
Wakamoto Pharmaceutical Co.,Ltd. Fundamentals Summary
| 4512 fundamental statistics | |
|---|---|
| Market cap | JP¥8.07b |
| Earnings (TTM) | -JP¥222.00m |
| Revenue (TTM) | JP¥9.43b |
0.0x
P/S Ratio0.0x
P/E RatioIs 4512 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4512 income statement (TTM) | |
|---|---|
| Revenue | JP¥9.43b |
| Cost of Revenue | JP¥4.35b |
| Gross Profit | JP¥5.08b |
| Other Expenses | JP¥5.30b |
| Earnings | -JP¥222.00m |
Last Reported Earnings
Mar 31, 2012
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4512 perform over the long term?
See historical performance and comparison